英科医疗(300677) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥2,972,240,252, a decrease of 33.88% compared to the same period last year[4] - Net profit attributable to shareholders was ¥1,063,692,657, down 56.61% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥1,061,299,771, reflecting a decrease of 56.64% compared to the previous year[4] - Basic earnings per share were ¥1.91, a decline of 62.10% year-on-year[4] - Operating revenue increased by 52.56% to CNY 13.65 billion compared to CNY 8.94 billion in the same period last year[10] - The company's net profit increased, leading to an 80.24% rise in undistributed profits to CNY 13.22 billion[10] - Total operating revenue for the current period reached ¥13,646,624,349, a significant increase of 52.5% compared to ¥8,944,921,087 in the previous period[26] - Operating profit for the current period was ¥8,102,312,098, up 54.8% from ¥5,262,527,377 in the previous period[29] - Net profit attributable to shareholders of the parent company was ¥6,942,508,781, representing a 58.7% increase from ¥4,372,579,432 in the previous period[32] - Basic earnings per share increased to ¥12.96 from ¥9.26, reflecting a growth of 39.1%[32] Assets and Liabilities - Total assets increased to ¥20,390,683,157, representing a growth of 57.64% from the end of the previous year[4] - Total current assets reached ¥11,534,143,128, an increase of 35.5% compared to ¥8,509,671,252 in the previous year[20] - Non-current assets totaled ¥8,856,540,029, up from ¥4,425,136,877, representing a growth of 100%[20] - Total liabilities increased to ¥4,772,205,746, compared to ¥3,492,052,605, reflecting a growth of 36.7%[23] - The company's equity attributable to shareholders rose to ¥15,375,370,657, up from ¥9,343,841,318, marking a growth of 64.7%[23] Cash Flow - The company reported a net cash flow from operating activities of ¥8,282,856,582, an increase of 60.25% year-on-year[4] - Cash flow from operating activities totaled ¥14,492,127,706, an increase of 42.3% compared to ¥10,210,073,253 in the previous period[33] - The company reported a net cash flow from operating activities of ¥8,282,856,582, an increase of 60.9% compared to ¥5,168,833,582 in the previous period[33] - The company experienced a 423.83% increase in net cash flow from investing activities, amounting to CNY -7.17 billion due to increased cash payments for land purchases and equipment[10] - Net cash flow from investment activities was -$7,171,068,481, compared to -$1,368,962,708 in the prior period, highlighting increased capital expenditures[36] - Net cash flow from financing activities was -$551,755,069, compared to -$430,110,470, suggesting ongoing challenges in financing[36] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 86,917[11] - The top shareholder, Liu Fangyi, holds 35.51% of the shares, totaling 195,155,523 shares[13] - The total number of restricted shares held by major shareholders increased to 171,300,797 shares, with 57,039,177 shares added during the period[16] Investments and Expenses - Research and development expenses grew by 36.26% to CNY 264.56 million, reflecting increased investment to meet customer demands[10] - Long-term borrowings surged by 335.94% to CNY 474.87 million, primarily due to an increase in long-term bank loans[10] - Deferred income increased by 181.61% to CNY 191.88 million, mainly due to an increase in government subsidies[10] - Financial expenses decreased significantly by 163.73%, resulting in a net financial income of CNY -77.93 million[10] - Total operating costs for the current period were ¥5,549,317,002, which is a 50.5% increase from ¥3,687,713,404 in the previous period[26] - Research and development expenses rose to ¥264,560,656, up 36.1% from ¥194,158,536 in the previous period[26] Inventory and Receivables - Accounts receivable rose by 58.15% to ¥817,461,490, primarily due to increased sales revenue[7] - The company reported a significant increase in accounts receivable, which rose to ¥817,461,490 from ¥516,880,911, a growth of 58.2%[17] - Inventory increased to ¥1,018,762,670, compared to ¥847,451,121 in the previous year, indicating a growth of 20.2%[20] Other Financial Information - Cash and cash equivalents amounted to ¥5,481,915,352, up from ¥5,009,383,540 in the previous year, reflecting a growth of approximately 9.4%[17] - The ending balance of cash and cash equivalents was $5,446,524,942, compared to $3,811,644,259, indicating a strong cash position[36] - The company did not apply the new leasing standards for the financial statements, which may impact future reporting[37] - The third-quarter report was not audited, which may affect the reliability of the financial data presented[39]